报告题目：癌症治疗用抗体：现状与发展趋势

报告时间：2011年9月7日(周三)13:30

报告地点：闵行校区实验B楼307室

报告人简介：Dr. Mitchell Ho（何苗壮）.Investigator and Chief of the Antibody Therapy Section at the National Cancer Institute (NCI). He received a B.S. degree from East China Normal University and a Ph.D. degree from the University of Illinois at Urbana-Champaign, where he studied monoclonal antibodies for the treatment of cocaine addiction as a National Research Service Award fellow. He was a postdoctoral fellow with Dr. Ira Pastan at the NCI where Dr. Ho contributed to the development of the recombinant immunotoxins which are currently evaluated in clinical trials for cancer treatment. Research in Dr. Ho’s laboratory at the NCI is aimed at developing human monoclonal antibodies for cancer therapy. He has over 18 years experience in monoclonal antibodies and antibody engineering, and was a research scientist at DNAX Research Institute and Protein Design Labs. He has published over 40 peer-reviewed manuscripts and obtained 6 patents. Dr. Ho is frequently invited to give lectures and chair symposia both nationally and internationally and has served on grant review panels for the U.S. National Institutes of Health (NIH) and Department of Defense (DOD). Dr. Ho is a recipient of the Mesothelioma Applied Research Foundation Award, the Ovarian Cancer Research Fund Individual Investigator Award, and the NCI Director''''s Intramural Innovation Award for Principal Investigators. He is currently the Chair of the NIH Antibody Interest Group and is on the Editorial Boards of Scientific Reports, mAbs, Antibodies and Journal of Cancer.

报告内容简介：Ever since Paul Ehrlich coined the term almost a century ago, scientists have been searching for ''''magic bullets'''' to fight diseases. The hybridoma fusion technology, developed by Köhler and Milstein in 1975, allowed for the first time, access to monoclonal antibodies (mAbs). MAbs that specifically target cancer cells while sparing normal tissues have become the most promising candidates for magic bullets against cancer. Since the debut of Rituximab (1997), eleven mAbs have been approved for cancer treatment. Despite their potential therapeutic benefit, the development of mAbs for cancer therapy has suffered from a number of serious problems. Unmet challenges continue to severely limit the number of mAbs that are able to move from the bench to the clinic. Such challenges concern several significant issues: (a) few viable tumor targets, and (b) limited anti-tumor efficacy (e.g. poor tumor penetration and unpredictable immunogenicity).